undamentalytics Newsletter
Sign in

Janux Therapeutics, Inc. cash flow statement

In fiscal 2025, Janux Therapeutics, Inc.'s operations generated −$82.2m of cash; it spent $1.0m on capital projects, leaving free cash flow of −$83.3m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−4−17−43−51−44−82−41
Depreciation and amortisation0012222
Stock-based pay071720334037
Capital spending0162011
Free cash flow−4−18−49−52−44−83−42
Free cash flow after stock pay−4−25−67−72−77−123−79

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CRSP vs JANXABEO vs JANXJANX vs STOK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Janux Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Janux Therapeutics, Inc.